Literature DB >> 23094220

Botulinum toxin in neurogenic detrusor overactivity.

Carlos Arturo Levi D'Ancona1, Rúiter Silva Ferreira, Mauricio Carneiro Rassi.   

Abstract

PURPOSE: To evaluate the effects of botulinum toxin on urodynamic parameters and quality of life in patients with neurogenic detrusor overactivity.
METHODS: Thirty four adult patients with spinal cord injury and detrusor overactivity were selected. The patients received 300 units of botulinum toxin type A. The endpoints evaluated with the episodes of urinary incontinence and measured the maximum cystometric capacity, maximum amplitude of detrusor pressure and bladder compliance at the beginning and end of the study (24 weeks) and evaluated the quality of life by applying the Qualiveen questionnaire.
RESULTS: A significant decrease in the episodes of urinary incontinence was observed. All urodynamic parameters presented a significant improvement. The same was observed in the quality of life index and the specific impact of urinary problems scores from the Qualiveen questionnaire. Six patients did not complete the study, two due to incomplete follow-up, and four violated protocol and were excluded from the analyses. No systemic adverse events of botulinum toxin type A were reported.
CONCLUSIONS: A botulinum toxin type A showed a significantly improved response in urodynamics parameters and specific and general quality of life.

Entities:  

Keywords:  Botulinum toxins; Overactive urinary bladder; Quality of life; Urodynamics

Year:  2012        PMID: 23094220      PMCID: PMC3469833          DOI: 10.5213/inj.2012.16.3.139

Source DB:  PubMed          Journal:  Int Neurourol J        ISSN: 2093-4777            Impact factor:   2.835


  25 in total

Review 1.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

2.  Quality of life of neurogenic patients: translation and validation of the Portuguese version of Qualiveen.

Authors:  Carlos Arturo Levi D'Ancona; José Tadeu Tamanini; Neury Botega; Nivaldo Lavoura; Ruiter Ferreira; Victor Leitão; Maria Helena Baena M Lopes
Journal:  Int Urol Nephrol       Date:  2008-06-05       Impact factor: 2.370

3.  Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.

Authors:  Gilles Karsenty; André Reitz; Gertraud Lindemann; Sönke Boy; Brigitte Schurch
Journal:  Urology       Date:  2006-12-04       Impact factor: 2.649

Review 4.  Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.

Authors:  Gary G Kay; Lisa J Granville
Journal:  Clin Ther       Date:  2005-01       Impact factor: 3.393

5.  Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial.

Authors:  Y-S Lee; M-S Choo; J Y Lee; S-J Oh; K-S Lee
Journal:  Int J Clin Pract       Date:  2011-09       Impact factor: 2.503

6.  Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.

Authors:  Brigitte Schurch; Marianne de Sèze; Pierre Denys; Emmanuel Chartier-Kastler; Francois Haab; Karel Everaert; Pierre Plante; Brigitte Perrouin-Verbe; Catherine Kumar; Stephanie Fraczek; Mitchell F Brin
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

7.  Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.

Authors:  Taha A Abdel-Meguid
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

8.  Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.

Authors:  Brigitte Schurch; Pierre Denys; Chris M Kozma; Pat Ray Reese; Terra Slaton; Richard L Barron
Journal:  Eur Urol       Date:  2007-04-19       Impact factor: 20.096

9.  Histologic features in the urinary bladder wall affected from neurogenic overactivity--a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A.

Authors:  Eva Compérat; André Reitz; Annick Delcourt; Frederique Capron; Pierre Denys; Emmanuel Chartier-Kastler
Journal:  Eur Urol       Date:  2006-02-06       Impact factor: 20.096

10.  European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.

Authors:  André Reitz; Manfred Stöhrer; Guus Kramer; Giulio Del Popolo; Emmanuel Chartier-Kastler; Jürgen Pannek; Harald Burgdörfer; Konrad Göcking; Helmut Madersbacher; Stefan Schumacher; Rudolf Richter; Jan von Tobel; Brigitte Schurch
Journal:  Eur Urol       Date:  2004-04       Impact factor: 20.096

View more
  1 in total

1.  The Role of OnabotulinumtoxinA in Urology: What Is the Next Step?

Authors:  Hong Sang Moon
Journal:  Int Neurourol J       Date:  2015-12       Impact factor: 2.835

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.